Admera Health Expands Oncology Test Portfolio with Launch of OncoGxSelect™ at the AMP 2016 Annual Meeting

SOUTH PLAINFIELD, N.J. and CHARLOTTE, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Molecular diagnostics company, Admera Health announced the official launch of OncoGxSelect™ while exhibiting at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina.  OncoGxSelect™ is a Next Generation Sequencing (NGS)-based test for tumor profiling of common cancer types, assaying 12 genes for mutations that align with well-established national guidelines for molecular testing and therapeutic decision making.  The panel genes are: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1.  Mutations in these genes are frequently the underlying driver of non-small cell lung cancer (NSCLC), melanoma, thyroid, gastrointestinal and breast cancers. Results from OncoGxSelect™ provide targeted therapy recommendations based on gene mutation and tumor type. In addition, relevant, recruiting clinical trials are reported.  

OncoGxSelect™ expands Admera’s Oncology Test Portfolio, which also includes OncoGxOne™, a comprehensive 64-gene tumor profiling panel, and PGxOne™ Plus, a pharmacogenomics panel that provides recommendations for over 220 commercial drugs, including cancer, anti-emetic and pain management drugs.

Guanghui Hu, PhD, President and CEO of Admera Health, commented, “The OncoGxSelect™ panel detects clinically actionable mutations that are associated with targeted therapies.” Hu went on to elaborate, “Although Admera already offered comprehensive tumor profiling, with this product launch we can now provide oncologists with a focused panel that follows well-accepted national clinical guidelines.”

Admera Health is exhibiting in Booth #2312 at the AMP 2016 Annual Meeting this week on November 10, 11 and 12.     

About Admera Health

Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.


Contact Data